Colleen Kusy
Stock Analyst at Baird
(0)
# 4047
Out of 5,218 analysts
51
Total ratings
36.11%
Success rate
-3.54%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Coherus BioSciences | Maintains: Outperform | 4 6 | 1.61 | 272.67% | 5 | Dec 5, 2024 | |
Enliven Therapeutics | Maintains: Outperform | 32 40 | 23.25 | 72.04% | 2 | Nov 15, 2024 | |
Spyre Therapeutics | Maintains: Outperform | 50 65 | 24.09 | 169.82% | 2 | Nov 13, 2024 | |
Apellis Pharmaceutic... | Maintains: Outperform | 92 55 | 33.24 | 65.46% | 10 | Nov 7, 2024 | |
Mersana Therapeutics | Maintains: Neutral | 4 3 | 2.15 | 39.53% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 18 17 | 8.67 | 96.08% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 35 37 | 17.03 | 117.26% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 27 25 | 8.51 | 193.77% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 105 | 86.68 | 21.14% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 160 | 3.03 | 5180.53% | 1 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 40 | n/a | n/a | 3 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 17 15 | n/a | n/a | 1 | Oct 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 17 14 | 0.7 | 1900% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 30 34 | 7.83 | 334.23% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 230 | 4.03 | 5607.2% | 1 | Nov 2, 2021 |